Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
34
PDSB Quote, Financials, Valuation and Earnings
Last price:
$0.86
Seasonality move
:
-8.46%
Day range:
$0.83 - $0.91
52-week range:
$0.70 - $2.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.04x
Volume:
379.7K
Avg. volume:
1M
1-year change:
-56.5%
Market cap:
$47.6M
Revenue:
--
EPS (TTM):
-$0.82
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
-- | -$0.20 | -- | -4.94% | $7.50 |
|
CLRB
Cellectar Biosciences, Inc.
|
-- | -$2.53 | -- | -20.45% | $47.00 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -63.28% | $64.47 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PAVM
PAVmed, Inc.
|
$12.5K | -$0.20 | 150% | -78.99% | $11.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
$0.87 | $7.50 | $47.6M | -- | $0.00 | 0% | -- |
|
CLRB
Cellectar Biosciences, Inc.
|
$3.77 | $47.00 | $6.8M | -- | $0.00 | 0% | 137.94x |
|
IMNN
Imunon, Inc.
|
$3.90 | $64.47 | $8.3M | -- | $0.00 | 0% | 16.43x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PAVM
PAVmed, Inc.
|
$0.33 | $11.00 | $9.1M | 0.30x | $0.00 | 0% | 293.08x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
65.52% | 0.936 | 37.29% | 1.97x |
|
CLRB
Cellectar Biosciences, Inc.
|
4.4% | 1.128 | 3.58% | 2.56x |
|
IMNN
Imunon, Inc.
|
21.26% | 4.145 | 10.13% | 1.25x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PAVM
PAVmed, Inc.
|
20.6% | 0.050 | 34.03% | 0.30x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PDSB
PDS Biotechnology Corp.
|
-$15.1K | -$8.1M | -91.45% | -196.47% | -- | -$5.9M |
|
CLRB
Cellectar Biosciences, Inc.
|
-$52.3K | -$4.9M | -154.34% | -160.56% | -- | -$4.3M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
PDS Biotechnology Corp. vs. Competitors
-
Which has Higher Returns PDSB or CLRB?
Cellectar Biosciences, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of --. PDS Biotechnology Corp.'s return on equity of -196.47% beat Cellectar Biosciences, Inc.'s return on equity of -160.56%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M -
What do Analysts Say About PDSB or CLRB?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 762.07%. On the other hand Cellectar Biosciences, Inc. has an analysts' consensus of $47.00 which suggests that it could grow by 1146.68%. Given that Cellectar Biosciences, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Cellectar Biosciences, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 CLRBCellectar Biosciences, Inc.2 2 0 -
Is PDSB or CLRB More Risky?
PDS Biotechnology Corp. has a beta of 1.107, which suggesting that the stock is 10.743% more volatile than S&P 500. In comparison Cellectar Biosciences, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.939%.
-
Which is a Better Dividend Stock PDSB or CLRB?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Cellectar Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or CLRB?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than Cellectar Biosciences, Inc. quarterly revenues of --. PDS Biotechnology Corp.'s net income of -$9M is lower than Cellectar Biosciences, Inc.'s net income of -$4.4M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Cellectar Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 137.94x for Cellectar Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M
-
Which has Higher Returns PDSB or IMNN?
Imunon, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of --. PDS Biotechnology Corp.'s return on equity of -196.47% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About PDSB or IMNN?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 762.07%. On the other hand Imunon, Inc. has an analysts' consensus of $64.47 which suggests that it could grow by 1553.01%. Given that Imunon, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Imunon, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 IMNNImunon, Inc.2 1 0 -
Is PDSB or IMNN More Risky?
PDS Biotechnology Corp. has a beta of 1.107, which suggesting that the stock is 10.743% more volatile than S&P 500. In comparison Imunon, Inc. has a beta of 1.937, suggesting its more volatile than the S&P 500 by 93.659%.
-
Which is a Better Dividend Stock PDSB or IMNN?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or IMNN?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. PDS Biotechnology Corp.'s net income of -$9M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns PDSB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of -255.85%. PDS Biotechnology Corp.'s return on equity of -196.47% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PDSB or NBY?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 762.07%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that PDS Biotechnology Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe PDS Biotechnology Corp. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PDSB or NBY More Risky?
PDS Biotechnology Corp. has a beta of 1.107, which suggesting that the stock is 10.743% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PDSB or NBY?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or NBY?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PDS Biotechnology Corp.'s net income of -$9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns PDSB or PAVM?
PAVmed, Inc. has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of -120220%. PDS Biotechnology Corp.'s return on equity of -196.47% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About PDSB or PAVM?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 762.07%. On the other hand PAVmed, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 3243.47%. Given that PAVmed, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe PAVmed, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 PAVMPAVmed, Inc.1 0 0 -
Is PDSB or PAVM More Risky?
PDS Biotechnology Corp. has a beta of 1.107, which suggesting that the stock is 10.743% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.
-
Which is a Better Dividend Stock PDSB or PAVM?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or PAVM?
PDS Biotechnology Corp. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. PDS Biotechnology Corp.'s net income of -$9M is lower than PAVmed, Inc.'s net income of -$6M. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus 293.08x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M PAVMPAVmed, Inc.293.08x 0.30x $5K -$6M
-
Which has Higher Returns PDSB or PTN?
Palatin Technologies has a net margin of -- compared to PDS Biotechnology Corp.'s net margin of --. PDS Biotechnology Corp.'s return on equity of -196.47% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PDSB or PTN?
PDS Biotechnology Corp. has a consensus price target of $7.50, signalling upside risk potential of 762.07%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than PDS Biotechnology Corp., analysts believe Palatin Technologies is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings PDSBPDS Biotechnology Corp.3 0 0 PTNPalatin Technologies0 0 0 -
Is PDSB or PTN More Risky?
PDS Biotechnology Corp. has a beta of 1.107, which suggesting that the stock is 10.743% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PDSB or PTN?
PDS Biotechnology Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PDS Biotechnology Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PDSB or PTN?
PDS Biotechnology Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. PDS Biotechnology Corp.'s net income of -$9M is higher than Palatin Technologies's net income of --. Notably, PDS Biotechnology Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PDS Biotechnology Corp. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PDSBPDS Biotechnology Corp.-- -- -- -$9M PTNPalatin Technologies-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
